AbGn-110 includes a potent cytotoxin designed to specifically targets antigen-expressing tumors. At the same time, in the selective killing, the novel drug does not harm healthy, normal cells.
AbGn-110 has shown to be superior in vitro cytotoxicity as well as more than 15-fold potent in vivo antitumor efficacy compared to reference Antibody-drug Conjugates.
Pre-clinical toxicity studies in rats and monkeys have demonstrated that AbGn-110 exhibited comparable or greater tolerability profile than its reference ADC. Based on the available data, this suggest that the trial drug substantially improves therapeutic index and could be highly beneficial for clinical treatment.
Except for skin cancers, breast cancer is the most common cancer among American women. According to the American Cancer Society, about 1 in 8 (12%) women in the United States will develop invasive breast cancer during their lifetime.
Gastric (stomach) cancer mostly affects older people. The average age of people when they are diagnosed is 69. On average, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Furthermore, the average risk that a person will develop stomach cancer in his or her lifetime is about 1 in 111.
Investigational New Drug
AbGn-110 is currently in IND-enabling stage of development and is expected to file an Investigational New Drug (IND) application in 2017. According to the researchers at AbGenomics, the investigational drug may offer an important opportunity for the patients who are not satisfied with the currently approved therapy.
AbGn-110 is a novel antibody-drug conjugate with a clinically validated targeting antibody and payload. AbGenomics’ proprietary linker and conjugation sites further reduce the non-targeted toxicity. In pre-clinical trials, AbGn-110 showed a more than 15-fold potency over its reference ADC. Furthermore, approximately 40% of breast cancer patients who have been treated with the reference ADC still required additional treatments.